ngµç×ÓÓÎÏ·

03
Ê×Ò³ / ½Ìѧ¿ÆÑÐ / ÕýÎÄ

ÁÖÌìì§¡¢»Æ½¡ÍŶӽÒÏþи¨Öú¼ªÎ÷Ëû±õ-˳²¬ÁªºÏÌæÀ×ÀûÖéµ¥¿¹ÖÎÁƵĢòÆÚÊÔÑéЧ¹û

¸å¼þȪԴ£º£º£ºËïÒÝÏɼÍÄîÒ½Ôº ±à¼­£º£º£ºÎâÁ¢¼á ÉóºË£º£º£ºËïÒ«±ó ÔĶÁÁ¿£º£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±·¿Ê«æÃ¡¢ÁõÎÄÇÙ¡¢»Æî££©¼¡²ã½þÈóÐÔ°òë×°©£¨MIBC£©Õ¼ËùÓаòë×Äò·ÉÏÆ¤°©±ÈÀýԼΪ25%£¬ £¬£¬ÆäÔ¤ºó½Ï²î£¬ £¬£¬»¼Õß5ÄêÉúÑÄÂÊȱ·¦50%¡£¡£¡£½üÄêÀ´£¬ £¬£¬Ëæ×ÅÃâÒß¼ì²éµãÒÖÖÆ¼ÁµÄ·ºÆð£¬ £¬£¬MIBCµÄи¨ÖúÖÎÁÆÈ¡µÃÁËÏÔÖøÏ£Íû¡£¡£¡£

¿ËÈÕ£¬ £¬£¬ngµç×ÓÓÎÏ·ËïÒÝÏɼÍÄîÒ½ÔºÁÖÌìì§½ÌÊںͻƽ¡½ÌÊÚÁìÏεĺ£ÄÚ¶àÖÐÐÄÁÙ´²Ñо¿£¨BGB-A317-2002£©Ì½ÌÖÁËÌæÀ×ÀûÖéµ¥¿¹ÁªºÏ¼ªÎ÷Ëû±õ/˳²¬Ð¸¨ÖúÖÎÁÆÖйúMIBC»¼ÕßµÄÁÆÐ§¡¢Çå¾²ÐÔ¼°Ç±ÔÚµÄÔ¤²âÐÔÉúÎï±ê¼ÇÎï¡£¡£¡£ÕâÏîÑо¿ÎªÖйúMIBC»¼ÕßµÄÖÎÁÆÌṩÁËÖ÷ÒªµÄѭ֤ҽѧ֧³Ö£¬ £¬£¬²¢ÓÚ2024Äê9ÔÂ10ÈÕ£¬ £¬£¬ÔÚ¹ú¼Ê¶¥¼¶ÆÚ¿¯¡¶Nature Cancer¡·ÉÏ£¬ £¬£¬½ÒÏþÁËÌâΪ¡¶Neoadjuvant gemcitabine¨Ccisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial¡±¡·µÄÂÛÎÄ¡£¡£¡£¸ÃÂÛÎĵÄͨѶ×÷ÕßΪÁÖÌìì§¡¢»Æ½¡½ÌÊÚ£¬ £¬£¬ÀîïÇÎĸ±Ö÷ÈÎҽʦºÍÖÓÎÄÁúÖ÷ÖÎҽʦΪÅäºÏµÚÒ»×÷Õß¡£¡£¡£

662E35C7C909771CEA0B8C4DD56_7A683C93_14AED

BGB-A317-2002Ñо¿ÊÇÒ»Ïî¶àÖÐÐÄ¡¢¿ª·Å±êÇ©¡¢µ¥±ÛµÄIIÆÚÁÙ´²ÊÔÑ飬 £¬£¬Ö¼ÔÚÆÀ¹ÀÌæÀ×ÀûÖéµ¥¿¹ÁªºÏ¼ªÎ÷Ëû±õ/˳²¬Ð¸¨ÖúÖÎÁÆÔÚÖйúMIBC»¼ÕßÖеÄÓÐÓÃÐÔ¡¢Çå¾²ÐÔ¼°Ô¤²âÉúÎï±ê¼ÇÎï¡£¡£¡£Ñо¿ÓÉngµç×ÓÓÎÏ·ËïÒÝÏɼÍÄîҽԺǣͷ£¬ £¬£¬Î÷°²½»Í¨´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥Êôͬ¼ÃÒ½Ôº¡¢°²»ÕÒ½¿Æ´óѧµÚ¶þÒ½Ôº¡¢±±¾©´óѧÈËÃñÒ½ÔººÍɽ¶«Ê¡Á¢Ò½ÔºµÈ¶¥¼¶ÃÚÄòÍâ¿ÆÖÐÐÄÅäºÏ¼ÓÈë¡£¡£¡£

Ñо¿µÄÖ÷ÒªÖÕµãΪ²¡ÀíÍêÈ«»º½âÂÊ£¨pCR£©£¬ £¬£¬´ÎÒªÖÕµã°üÀ¨ÊÂÎñÎÞÏ£ÍûÉúÑÄ£¨EFS£©¡¢ÎÞ¸´±¬·¢ÑÄ£¨RFS£©¡¢×ÜÉúÑÄÂÊ£¨OS£©¼°Çå¾²ÐԵȡ£¡£¡£ÔÚ57Àý½ÓÊܸùÖÎÐÔÊÖÊõµÄ»¼ÕßÖУ¬ £¬£¬pCRÂÊ´ï50.9%£¬ £¬£¬ÇкÏÔ¤ÉèµÄͳ¼ÆÑ§Öյ㣬 £¬£¬ÌáÐѸÃÖÎÁÆ·½°¸¾ßÓÐÆð¾¢µÄÁÙ´²ÒâÒå¡£¡£¡£×îеÄËæ·ÃÊý¾ÝÏÔʾ£¬ £¬£¬1ÄêEFS¡¢OSºÍRFSÂÊ»®·ÖΪ89.3%¡¢91.2%ºÍ85.2%¡£¡£¡£±ðµÄ£¬ £¬£¬¸Ãи¨ÖúÖÎÁÆ·½°¸µÄÇå¾²ÐÔºÍÄÍÊÜÐÔÓÅÒì¡£¡£¡£ÉúÎï±ê¼ÇÎïÑо¿ÏÔʾ£¬ £¬£¬ÃâÒßÑ×Ö¢±íÐÍ×黼ÕßµÄpCRÂʸߴï80%¡£¡£¡£

ÀúÊ·ÉϵÄи¨Öú»¯ÁÆ·½°¸£¬ £¬£¬pCRÂÊ£¨²¡ÀíÍêÈ«»º½âÂÊ£©Í¨³£Îª21%-30%£¬ £¬£¬pDSÂÊ£¨²¡Àí½µÆÚÂÊ£©Í¨³£Ð¡ÓÚ50%£¬ £¬£¬¶ø±¾Ñо¿µÄpCRºÍpDSÂʽÏÀúÊ·Êý¾Ý¾ùÌá¸ßÁË20%ÒÔÉÏ¡£¡£¡£±ðµÄ£¬ £¬£¬±¾Ñо¿ÖÐcT2»¼Õߣ¨ÁÙ´²Õï¶ÏΪT2ÆÚÖ×ÁöµÄ»¼Õߣ©µÄpCRÂʺÍpDSÂÊ»®·ÖµÖ´ï55.6%ºÍ86.1%£¬ £¬£¬¸ßÓÚÒÔÍùµÄÑо¿Êý¾Ý¡£¡£¡£Í¬Ê±£¬ £¬£¬ÓëÆäËûÃâÒßÁªºÏ˳²¬»¯ÁƵÄÑо¿Ïà±È£¬ £¬£¬±¾Ñо¿µÄpCRÂÊ£¨33%-49%£©Ò²ÓâÔ½ÁËÒÔÍùÑо¿µÄÉÏÏÞ¡£¡£¡£

ÖµµÃ×¢ÖØµÄÊÇ£¬ £¬£¬±¾Ñо¿Ì½Ë÷ÁËÓëи¨ÖúÃâÒßÁªºÏÖÎÁÆÓ¦´ðÏà¹ØµÄDZÔÚÉúÎï±ê¼ÇÎ £¬£¬È·¶¨ÁËÈýÖÖMIBC£¨¼¡²ã½þÈóÐÔ°òë×°©£©ÑÇÐÍ£º£º£ºS1£¨ÃâÒß»ÄÔ­±íÐÍ£©¡¢S2£¨ÃâÒßÇãÔþ±íÐÍ£©ºÍS3£¨ÃâÒßÑ×Ö¢±íÐÍ£©£¬ £¬£¬ÏÔʾÁËÔÚи¨ÖúÃâÒß»¯ÁÆÖÐÔ¤²â»ñÒæ»¼ÕßµÄDZÁ¦¡£¡£¡£

±¾Ñо¿Äý¾ÛÁ˺£ÄÚ6¼Ò´óÐÍÃÚÄòÍâ¿ÆÖÐÐĵÄÁÙ´²ÂÄÀú£¬ £¬£¬ÀúʱÎåÄ꣬ £¬£¬×îÖÕ½ÒÏþÔÚ¡¶Nature Cancer¡·ÕâÒ»¹ú¼Ê¶¥¼¶ÆÚ¿¯ÉÏ¡£¡£¡£ÔÚÁÆÐ§·½Ã棬 £¬£¬¸Ã·½°¸ÔÚpCRºÍpDSÂÊÉÏ´¦ÓÚ¹ú¼ÊͬÀàÑо¿µÄÁìÏÈλÖᣡ£¡£Ñо¿ÎªÖйúMIBC»¼Õßи¨ÖúÃâÒßÁªºÏ»¯ÁƵÄÁÙ´²Ó¦ÓÃÌṩÁËÖ÷ÒªµÄÖ¤¾Ý£¬ £¬£¬¾ßÓм«´óµÄÁÙ´²Íƹã¼ÛÖµ¡£¡£¡£

Ô­ÎÄÁ´½Ó£º£º£ºhttps://doi.org/10.1038/s43018-024-00822-0


¡¾ÍøÕ¾µØÍ¼¡¿